JPRN-UMIN000007135
Completed
未知
Study on effective prevention of chemotherapy-induced nausea and vomiting based on genetic polymorphism - Clinical pharmacogenetics study for antiemetic therapy
nivercity of Shizuoka0 sites180 target enrollmentJanuary 25, 2012
ConditionsBreast Cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- nivercity of Shizuoka
- Enrollment
- 180
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Known prior severe hypersensitivity to anthracyclines, cyclophosphamide, 5HT3 receptor antagonist, corticosteroids and NK\-1 receptor antagonists 2\) Patients who do not have enough whole body state to the antineoplastic agents treatment 3\) Pregnant, breastfeeding or expecting woman 4\) Patient with severe uncontrollable diabetes mellitus 5\) Known symptomatic brain metastasis 6\) Other clinical difficulties in this study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Music therapy for chemotherapy induced nausea and vomitingACTRN12622001495718Flinders Foundation24
Completed
Phase 2
Fenretinide in Treating Patients With Leukoplakia of the MouthHead and Neck CancerNCT00004161University of Alabama at Birmingham30
Completed
Phase 1
Oltipraz in the Prevention of Lung Cancer in People Who SmokeLung CancerNCT00006457Northwestern University
Terminated
Phase 2
SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the MouthHead and Neck CancerNCT00003223SWOG Cancer Research Network5
Completed
Phase 2
Iloprost in Preventing Lung Cancer in Patients at High Risk for This DiseaseLung CancerPrecancerous ConditionNCT00084409University of Colorado, Denver152